Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Chear Center LLC

Neither a doctor nor a teaching hospital

Research payments

$6,185,686

432 payments

Through program year 2025, Chear Center LLC is reported as receiving $6,185,686 in research payments, across 432 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $684,876 18
2024 Research $1,082,414 68
2023 Research $2,153,198 108
2022 Research $1,067,683 66
2021 Research $290,952 27
2020 Research $204,479 42
2019 Research $702,084 103

Breakdown

Who paid Research payments · program years 2019–2025
  1. Bavarian Nordic A/S $1,997,829 78 payments
  2. Genentech, Inc. $1,251,976 52 payments
  3. AstraZeneca Pharmaceuticals LP $741,793 29 payments
  4. Pfizer Inc. $477,260 42 payments
  5. Merck Sharp & Dohme Corporation $446,019 39 payments
  6. GlaxoSmithKline, LLC. $399,454 33 payments
  7. Intercept Pharmaceuticals, Inc. $180,585 33 payments
  8. Applied Therapeutics, inc. $105,764 10 payments
  9. AstraZeneca UK Limited $93,741 3 payments
  10. Vanda Pharmaceuticals Inc. $74,350 13 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age $1,266,508 48 payments
  2. Roche Cancer Screening Collection Study $1,251,976 52 payments
  3. Nct05238025 $731,320 30 payments
  4. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $402,891 24 payments
  5. A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction $350,079 13 payments
  6. A Phase IV, 12-Week, Randomised, Double-Blind, Triple Dummy Study to C $259,398 11 payments
  7. A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler $209,906 3 payments
  8. A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension $171,748 3 payments
  9. 1009742 $161,428 27 payments
  10. Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy $105,764 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record